Abstract
Background: Management of diabetes during fasting is a significant clinical challenge. Sodium glucose co-transporter-2 inhibitors (SGLT2i) are a new class of anti-diabetic medications considered safe with low risk of hypoglycaemia. However, there are only limited number of studies studying SGLT-2 inhibitors during Ramadan and none studying empagliflozin in comparison with Dipeptidyl Peptidase 4 (DPP4) inhibitors.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
